See on Scoop.it – MyHealthShare Medical Reporter
Jazz Pharmaceuticals Plc (JAZZ), the maker of the narcolepsy treatment Xyrem, said it will buy Gentium SpA (GENT), a rare disease drug developer, in a deal valued at $1 billion. Jazz, based in Dubl…
See on globalgenes.org
Advertisements